[Study of a carrier solution for the lidocaine infusion therapy in myocardial infarct].
Corafusin, an infusion solution containing lidocaine, electrolytes and sorbitol, was tested during 4-day continuous infusion of patients with myocardial infarction. The serum sodium level remained constant within the normal range whereas initially reduced serum potassium and magnesium concentration increased to normal within 24 hours. Both sodium and water balance were generally equilibrated during the entire test period. Testing of lactate and non-esterified fatty acids revealed a significant decrease within the first 24 hours. On the basis of these findings it can be concluded that the infusion solution tested is suited for lidocaine infusion therapy of patients with myocardial infarction.
D004573:Electrolytes / Q000378:metabolism*; D006706:Homeostasis; D006801:Humans; D007263:Infusions, Parenteral; D008012:Lidocaine / Q000008:administration & dosage* / Q000627:therapeutic use; D008274:Magnesium / Q000378:metabolism; D009203:Myocardial Infarction / Q000188:drug therapy*; D011188:Potassium / Q000378:metabolism; D012964:Sodium / Q000378:metabolism; D013012:Sorbitol / Q000378:metabolism
D004573:Electrolytes; D013012:Sorbitol; D008012:Lidocaine; D012964:Sodium; D008274:Magnesium; D011188:Potassium
Prüfung einer Trägerlösung für die Lidocain-Infusionstherapie bei Myokardinfarkt.